Skip to content
Sanofi Consumer Healthcare logo

Sanofi Consumer Healthcare India

SANOFICONR NSE
₹3,472.60 −23.30 (−0.67%)
P/E
30.07
View as Markdown
MCP
Close 4 Nov 2026 ₹3,472.60 −1,244.50 −26.4% 1Y
Start ₹4,717.10

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
89.90%
Debt to Equity
0.06
EPS (TTM)
₹115.49
Book Value
₹151.07
Market Cap
—
P/E (TTM)
30.07
P/B
22.99
ROE
71.60%
Dividend Yield
2.15%
EBITDA
₹327 Cr
52W High
₹5,255.00
52W Low
₹3,168.20
Day Range
₹3,435.00 – ₹3,528.50
Volume
5,077

Peer Comparison

Healthcare › Pharmaceuticals

Sanofi Consumer Healthcare peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Sanofi Consumer Healthcare (this company)
₹3,472.6030.07₹8,015 Cr22.992.15%71.60%89.90%₹950 Cr₹266 Cr
Median 8 companies₹2,048.6037.20₹1,25,337 Cr7.290.70%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

56 Good

Data confidence 98/100

Category scores

Quality
62
Good
Returns, margins, earnings quality 22% weight
Valuation
53
Average
Cheap vs sector & own history 24% weight
Growth
81
Strong
Sales & profit trajectory 9% weight
Financial Health
82
Strong
Solvency, leverage, coverage 9% weight
Momentum
13
Poor
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 77.6%
  • Company has been maintaining a healthy dividend payout of 49.3%

Weaknesses

1
  • Stock is trading at 22.7 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1054
OscillatorsNeutral252
Moving AveragesStrong Bearish802

Key readings

RSI (14)
42.73
Neutral
MACD (12,26,9)
−110.59
Bullish
SMA (50)
3,809.82
Bearish
SMA (200)
4,316.89
Bearish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 1Y: fiscal year to Dec 2025 against Dec 2024; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
1Y+21.27%
TTM+31.03%

Net profit

Net profit growth by window
1Y+32.60%
TTM+33.00%

Operating cash flow

Operating cash flow growth by window
1Y−60.14%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
1Y−2.24 pp
TTM+1.44 pp

Revenue by year

Revenue by year, ₹ crore
Dec 2024₹724 Cr
Mar 2025₹878 Cr
Dec 2025₹878 Cr

Net profit by year

Net profit by year, ₹ crore
Dec 2024₹181 Cr
Mar 2025₹240 Cr
Dec 2025₹240 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹379 Cr +35.4% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk medium

Sanofi Consumer Healthcare India Ltd trades at a market cap of ₹10,640 Cr with a PE of 41.3x and price-to-book of 27.76x. The company delivered TTM sales growth of 38% and profit growth of 35%, while maintaining a 3-year ROE of approximately 78% with virtually no debt on its balance sheet.

Bull Case 8
  • Company is almost debt-free, providing significant financial flexibility and resilience against interest rate cycles
  • Exceptional 3-year ROE of 78% indicates highly efficient capital allocation and strong competitive moat in its product portfolio
  • TTM compounded sales growth of 38% demonstrates robust top-line momentum in the consumer healthcare segment
  • TTM compounded profit growth of 35% shows strong earnings acceleration alongside revenue growth
  • Last year ROE of 72% confirms consistent high returns are being sustained, not a one-off occurrence
  • Healthy dividend payout ratio of 49.3% with a current yield of 1.62% provides regular income to shareholders
  • Backed by global Sanofi parentage, offering access to R&D pipelines, brand equity, and operational best practices in consumer healthcare
  • Company is expected to deliver a good upcoming quarter based on operational trends, potentially extending the growth streak
Bear Case 6
  • PE ratio of 41.3x is significantly above the broader market average, pricing in substantial future growth that must be delivered consistently
  • Stock price has declined 14% over the past 1 year, indicating negative price momentum despite strong fundamentals
  • Limited long-term historical data available — 5-year and 10-year CAGR figures for sales, profit, and stock returns are not reported, making long-term trend assessment difficult
  • 52-week high and low data are unavailable (showing 0), limiting ability to assess current price relative to recent trading range
  • Market cap of ₹10,640 Cr in a niche consumer healthcare segment may constrain institutional interest and liquidity compared to larger pharma peers
  • High ROE of 72-78% partly reflects a very low equity base (as evidenced by 27.76x P/B), which can amplify apparent returns without proportional economic value creation

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Sanofi Consumer Healthcare India is returning significant cash to shareholders with a Rs 75/share dividend for FY25, reflecting healthy profitability. No headwinds or risks are visible from recent news flow. With limited public information beyond the dividend announcement, the outlook appears stable but warrants monitoring for operational updates.

Positives 1
  • Rs 75 final dividend declared Jun 26

    Sanofi Consumer Healthcare India declared a final dividend of Rs 75 per share for FY25 at its 3rd AGM held on June 26, 2026, signaling strong cash generation and shareholder return commitment.

Quarterly Results

₹ Cr
SANOFICONR quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
210
225
222
172
160
171
173
221
234
251
229
236
263
Expenses
116
135
140
109
97
109
109
151
149
161
140
146
161
Operating Profit
95
90
82
64
63
62
64
70
85
90
89
89
102
OPM %
45%
40%
37%
37%
39%
36%
37%
32%
36%
36%
39%
38%
39%
Other Income
1
1
3
−24
4.2
2
5
12
3
5
6
6
4
Interest
0
0
0
0
3
0
0
0
1
0
0
0
0
Depreciation
1
1
1
1
2
1
2
3
3
3
3
3
3
PBT
95
90
84
39
61
63
67
79
84
90
91
92
103
Tax %
25%
24%
25%
25%
26%
29%
25%
23%
25%
27%
25%
25%
25%
Net Profit
71
68
63
29
45
44
50
61
63
66
68
69
77
EPS (₹)
—
—
—
12.59
19.54
19.24
21.71
26.36
27.31
28.87
29.44
29.87
—

Sep 2026: from the results filed on 28 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
SANOFICONR profit and loss, annual, ₹ crore
Particulars Dec 2023 8mDec 2024Mar 2025Dec 2025TTM
Sales
555
724
878
878
950
Expenses
337
454
569
569
597
Operating Profit
219
271
309
309
353
OPM %
39%
37%
35%
35%
37%
Other Income
2
−15
25
25
20
Interest
0
4
2
2
2
Depreciation
2
4
12
12
13
PBT
219
247
320
320
357
Tax %
25%
27%
25%
25%
—
Net Profit
165
181
240
240
266
EPS (₹)
—
78.59
104
104
115
Div. Payout %
6%
70%
0%
72%
—

Balance Sheet

₹ Cr
SANOFICONR balance sheet, annual, ₹ crore
Particulars Dec 2023Dec 2024Dec 2025Jun 2026
Equity Capital
2
23
23
23
Reserves
206
250
361
325
Borrowings
0
20
25
21
Other Liabilities
138
138
138
338
Total Liabilities
345
431
547
706
Fixed Assets
5
29
36
30
CWIP
3
1
0
0
Investments
0
0
0
0
Other Assets
338
402
511
677
Total Assets
345
431
547
706

Cash Flow

₹ Cr
SANOFICONR cash flow, annual, ₹ crore
Particulars Dec 2023Dec 2024Mar 2025Dec 2025
Operating
0
439
—
175
Investing
0
2
—
8
Financing
2
−116
—
−134
Net Cash Flow
2
325
—
48
Free Cash Flow
−4
429
—
167
CFO/EBITDA
2
208
—
85

Ratios

SANOFICONR financial ratios, annual
Particulars Dec 2023Dec 2024Mar 2025Dec 2025
Debtor Days
21
7
—
12
Inventory Days
232
80
—
98
Days Payable
144
138
—
126
Cash Conversion Cycle
109
−51
—
−16
Working Capital Days
134
−33
—
−4
ROCE %
—
111%
—
90%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sanofi Consumer Healthcare insights

57 extracted metrics across FY23–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 71.27%
  • DIIs 18.03%
  • Public 6.16%
  • FIIs 2.48%
  • Others 2.06%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Sanofi Consumer Healthcare India

What does Sanofi Consumer Healthcare India Ltd do?
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products. It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products.
Where is Sanofi Consumer Healthcare India Ltd (SANOFICONR) listed?
Sanofi Consumer Healthcare India Ltd trades as SANOFICONR on the NSE and under code 544250 on the BSE.
Which sector does Sanofi Consumer Healthcare India Ltd belong to?
Sanofi Consumer Healthcare India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd trades at a PE ratio of 30.07 as of 4 Nov 2026, on earnings per share of ₹115.49, against a book value of ₹151.07 per share.
What is the 52-week high and low of Sanofi Consumer Healthcare India Ltd?
Over the last 52 weeks Sanofi Consumer Healthcare India Ltd has traded between ₹3,168.2 and ₹5,255 as of 4 Nov 2026.
Does Sanofi Consumer Healthcare India Ltd pay dividends?
Sanofi Consumer Healthcare India Ltd has a dividend yield of 2.15%.
What is the Return on Equity (ROE) of Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd reported a return on equity of 71.60%. Its debt-to-equity ratio is 0.06.

Company Information

Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products. It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products.

Website sanofi.in
Listed 13 Sep 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SANOFICONR.md for Sanofi Consumer Healthcare India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month